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ABSTRACT
B-cell malignancies constitute a large part of hematological neoplasias. They 
represent a heterogeneous group of diseases, including Hodgkin’s lymphoma, most 
non-Hodgkin’s lymphomas (NHL), some leukemias and myelomas. B-cell malignancies 
reﬂect deﬁned stages of normal B-cell differentiation and this represents the major 
basis for their classiﬁcation. Long non-coding RNAs (lncRNAs) are non-protein-
coding transcripts longer than 200 nucleotides, for which many recent studies 
have demonstrated a function in regulating gene expression, cell biology and 
carcinogenesis. Deregulated expression levels of lncRNAs have been observed in 
various types of cancers including hematological malignancies. The involvement of 
lncRNAs in cancer initiation and progression and their attractive features both as 
biomarker and for therapeutic research are becoming increasingly evident. In this 
review, we summarize the recent literature to highlight the status of the knowledge of 
lncRNAs role in normal B-cell development and in the pathogenesis of B-cell tumors.
INTRODUCTION
LncRNAs are a highly heterogeneous group of 
RNA molecules longer than 200 nucleotides accounting 
for more than half of the mammalian non-coding 
transcriptome. The definitive number of human lncRNA 
transcripts is still unknown; the repository LNCipedia 
currently contains 118,777 human annotated lncRNAs, 
with many loci generating multiple transcripts [1]. There 
is an exponential interest in investigating lncRNAs 
as considerable evidence suggests a huge impact of 
lncRNAs on several molecular mechanisms. LncRNA 
expression is regulated during development, and can be 
tissue- and cell-type specific. The mechanisms underlying 
the function of most lncRNAs are not fully understood. 
The structural versatility of lncRNAs might be crucial 
to form binding sites for the interaction with proteins, 
DNA, and other RNA molecules by serving as guides, 
tethers, decoys, and scaffolds. From a functional point 
of view, lncRNAs regulate gene expression at multiple 
levels including transcriptional, post-transcriptional, 
and chromatin modification (reviewed in [2-8]). For 
instance, they can directly act, either in cis or in trans, 
on the genomic DNA to regulate gene expression. To this 
end, they may recruit chromatin-modifying complexes 
dictating the conformation of heterochromatin that 
represses transcription, or they may activate transcription 
by either triggering enhancer regions or inducing three 
dimensional chromatin conformation changes. Other 
lncRNAs can interact with transcription factors and 
RNA-binding proteins to indirectly regulate transcription. 
With a different mechanism, lncRNAs can indirectly 
alter gene expression by competing with mRNAs for 
miRNA binding. LncRNAs can also act regulating mRNA 
processing events such as splicing, editing, localization, 
translation and turnover/degradation (Figure 1). 
LncRNAs expression is involved in oncogenic or 
tumor suppressor processes [9]. Moreover, it has been 
reported in many types of tumors that dysregulation 
of distinct lncRNAs promotes cancerogenesis, disease 
progression, and metastasis [10, 11]. An increasing 
number of evidence suggests that lncRNAs are leading 
actors both in normal and malignant hematopoiesis 
(reviewed in [12-16]). 
We have recently reviewed the current knowledge 
about lncRNAs involvement in normal hematopoiesis 
and in hematological tumors. The data available thus far 
suggest that several lncRNAs may have a prospective 
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clinical significance in the diagnosis, prognosis, and 
therapy of these malignancies.
An additional chapter deserve B-cell malignancies 
that constitute a large part of hematological neoplasias. 
They represent a heterogeneous group of diseases, 
including Hodgkin’s lymphoma, most non-Hodgkin’s 
lymphomas (NHL), some leukemias and myelomas. 
B-cell malignancies mirror specific stages of normal 
B-cell differentiation and this represents the major basis 
for their classification. This review focuses on lncRNA 
involvement in normal human B-cell differentiation and 
in the pathogenesis and natural history of B-cell tumors. 
B-CELL DIFFERENTIATION
In adults, B-cell differentiation begins within bone 
marrow (BM) and concludes in the peripheral secondary 
lymphoid organs, such as lymph nodes, tonsils, and spleen.
B-cell differentiation in the BM passes through 
different cellular stages including the common lymphoid 
progenitor, pro-B cell, pre-B cell and immature-B cell 
stages [17]. These stages are demarcated by consecutive 
steps of the process of somatic recombination that 
assembles different gene portions within the heavy or light 
chain loci to produce functional B cell receptor (BCR)/
immunoglobulin (Ig) genes. Specifically, the somatic 
rearrangement of the Variable (V), Diversity (D) and 
Joining (J) gene segments with the Constant (C) region 
exons gives rise to heavy chains Igs with unique antigenic 
specificity. The light chains rearrange in a very similar 
way, but do not have D gene segments. Fruitful assembly 
of heavy and light chains results in the expression of 
complete IgM molecule at the surface of immature B-cell 
that, once tested for auto-reactivity by the immune system, 
leaves the BM and migrates via the blood and the lymph to 
the secondary lymphoid organs.
Figure 1: LncRNAs in epigenetic, transcriptional and translational regulation. Nine mechanisms of epigenetic, transcriptional 
and translational regulation by lncRNAs are shown. A. LncRNAs act as a transcriptional guide by recruiting chromatin-modifying enzymes 
to target genes with activator (blue) or repressive (violet) histone marks. B. LncRNAs control the recruitment of transcription factors (TF) 
and core components of the transcriptional machinery. C. LncRNAs act as a transcriptional guide by accosting enhancer elements. D. 
LncRNAs bind mRNAs and splicing factors (SF) and modulate splicing processing. E. LncRNAs participate in the higher order organization 
of the nucleus by mediating spatial conformation of chromosomes and F. as structural components for the formation and function of nuclear 
bodies. G. LncRNAs modulate mRNA decay protecting mRNA from degradation or, alternatively, mediating the recruitment of degradation 
machinery. H. LncRNAs can act as miRNA sponges, thus favoring the expression of the mRNAs targeted by the sequestered miRNA. I. 
LncRNAs control translation rates favoring or inhibiting polysome loading to mRNAs.
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In the periphery B-cells differentiate to the mature or 
naïve stage in the absence of any contact with exogenous 
antigens [18]. The encounter with an antigen establishes 
the second phase of B-cell maturation. More specifically, 
once bound to an antigen, the B-cell enters into primary 
lymphoid follicles of peripheral lymphoid tissues resulting 
in the formation of germinal centers (GCs). In the GC a 
dark and a light zone can be distinguished. The dark 
Table 1: LncRNAs with roles in normal B-cells
lncRNA(s)/
alias Stage of B-cell Genome location Function Molecular mechanism Reference(s)
MYB-AS1, 
SMAD1-AS1, 
LEF1-AS1
pre-B1 and 
pre-B2 cells
6q23.3, 4q31.21, 
4q25
Involvement in early 
B-cell development
Antisense transcripts to 
TFs with well-known 
roles in early B-cells
[23]
CRNDE
pre-B1, pre-B2, 
CBs and, to a 
lesser extent, 
CCs
16q12.2
Involvement in mitotic 
cell cycle related 
processes
Promotion of the 
metabolic changes 
by which cancer cells 
switch to aerobic 
glycolysis
[23, 25-27]
RP11-
132N15.3/
lnc-BCL6-3
CBs and, to a 
lesser extent, 
CCs
3q27.3
Involvement in the 
modulation of the GC 
reaction
LincRNA possibly 
regulating the 
transcriptional repressor 
BCL-6
[23]
Abbreviations: CC, centrocyte; CB, centroblast; GC, germinal center
Figure 2: LncRNAs expressed in B-cell differentiation or pathology. B-cell differentiation in BM and lymphoid tissue with 
distinct types of B-cell malignancies originating from cells blocked at different stages of maturation. B-ALL cells resemble Pro/Pre-B 
lymphocytes; CLL originate from naïve or activated unmutated IGHV B-cells in the marginal zone or from mutated IGHV committed 
memory B-cell; MCL are like B-cells from the mantle zone; BL resemble dark zone B-cells; FL and GC-DLBCL originate from light zone 
B-cells; ABC-DLBCL show characteristic of late GC B-cells; MM and PCL originate from mature PCs. Differentially expressed lncRNAs 
are reported for each stage of B-cell maturation, and for distinct B-cell malignancies as compared to normal B-cell.
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Table 2: Most frequently deregulated lncRNAs in malignant B-cells
lncRNA(s)/ alias Disease type Genome location Functiona Molecular mechanism References
BALR-1/
c14orf132 B-ALL 14q32.2 U Not described [35]
BALR-2 B-ALL 7q21.2 U
Inhibition of genes downstream of the 
glucocorticoid receptor (FOS, JUN, 
BIM)
[35]
BALR-6 B-ALL 3p24.3 U Possible regulation of the transcriptome downstream of SP1 [35, 36]
LINC00958/
LOC1506305 B-ALL 11q15.2 U Not described [35]
DLEU2 CLL,MM 13q14.3 TS
NF-kB activation. 
Host of miR-15a/16-1 cluster targeting 
BCL2
[42-48, 111]
NEAT1 CLL 11q13.1 TS Induced by p53 [49, 52, 53]
lincRNA-p21/
TP53COR1 CLL, DLBCL
17p13.1
(mouse)
6p21.2 (human)
TS
Induced by p53.
Functionally linked to Cyclin D1, 
CDK4 and p21 in human DLBCL 
tissues
[49-51, 88]
MIAT CLL 22q12.1 O Constitution of a regulatory loop with OCT4 [54-57]
ZNF667-AS1/
lnc-AC004696.1-1 CLL 19q13.43 U Not described [60, 61]
BM742401 CLL 18q11.2 TS Not described [58, 59]
BIC CLL 21q21 OnP Host of miR-155-5p and miR-155-3p [29-31, 132, 133]
lnc-IRF2-3 CLL 4q35 U Not described [61]
lnc-KIAA1755-4 CLL 20q11.23 U Not described [61]
GAS5 MCL, DLBCL, MM 1q25.1 TS
Required for the inhibitory effects of 
mTOR antagonists.
Regulated by mTOR pathway
[65-73, 111, 
134]
MALAT1 MCL,MM 11q13 O
SP1 recruitment to the promoter 
of LTBP3 gene regulating the 
bioavailability of TGF-β.
[74-76, 110-
114]
RP11-625 L16.3 FL 12 U Not described [80]
LOC283177 DLBCL 11q25 U Not described [85]
lnc-RP11-
211G3.3.1-1 DLBCL 3q27.3 U Not described [84]
LUNAR1 DLBCL 15q26.3 O
Regulated by NOTCH1.
Enhancement of IGF1R mRNA 
expression 
[86, 87]
PEG10 DLBCL 7q21.3 O Activated by c-MYC [89-91]
HULC DLBCL 6p24.3 O Not described [92-95]
HOTAIR DLBCL 12q13.13 O Regulation of the PI3K/AKT/NF-κB pathway [96]
MINCR BL 8q24.3 U Induced by MYC [103]
MEG3 MM 14q32.2 TS
Interaction with p53.
Regulation of P53 gene expression. 
Enhancement of the expression of 
BMP4 gene in MM-MSCs.
[115-117]
TUG1 MM 22q12.2 O
PRC2 binding to repress cell-cycle 
regulation genes.
Induced by p53
[112, 118]
Oncotarget5www.impactjournals.com/oncotarget
zone is formed by centroblasts (CBs), which are rapidly 
dividing B-cells that achieve further diversification of the 
Ig repertoire through the somatic hypermutation of the 
V regions of Ig genes [19]. CBs eventually differentiate 
into non-cycling centrocytes (CCs), which constitute 
the light zone of the GC. The CCs are able to generate 
new antibody variants that are selected according to their 
affinity to the cognate antigen, ensuring increased affinity 
between the Ig and the antigen. In addition, a fraction 
of CCs can undergo Ig class switching by somatic DNA 
recombination, thus generating antibodies with different 
effector functions. Finally, B-cells leave the GC rapidly 
differentiating into long-lived PCs or memory B-cells, 
otherwise they might re-enter the dark zone and reiterate 
the cycle [20-22].
LncRNAs IN B-CELL DIFFERENTIATION
The role of lncRNAs in normal human B-cell 
differentiation remains to be fully elucidated (see Figure 
2 and Table 1 for details on lncRNAs discussed in the text 
below).
The identification of lncRNAs specifically expressed 
during different stages of human B-cell development 
has been recently analyzed by Petri et al. [23]. Eleven 
distinct B-cell subsets separated by flow cytometry, 
including pre-B1, pre-B2, immature, naïve, memory, and 
PCs from BM biopsies, and naïve, CB, CC, memory, 
and plasmablast cells from tonsil tissues, respectively, 
were subjected to microarray expression analysis. This 
study pointed out numerous lncRNAs belonging to well-
defined gene networks linked to precise steps of cellular 
differentiation. Notably, among sequences expressed 
mainly in pre-B1 and pre-B2 cells, Petri et al. identified 
several lncRNAs, including antisense transcripts (SMAD1-
AS1, MYB-AS1, and LEF1-AS1) to transcription factors 
known to have a function in early B-cells. Although 
the role of these lncRNAs in B-cell development is still 
unknown, their crucial positions in the gene co-expression 
network analysis suggest key functions in the early stages 
of cellular differentiation. In the co-expression module 
including genes that display highest expression levels in 
pre-B1, pre-B2 cells, and CBs, and low ones in CCs, were 
found overexpressed genes involved in processes related 
to mitosis and cell cycle control, consistently with the high 
proliferative activity of both pre-B cells and GC CBs [24]. 
Among lncRNAs showing strong and highly significant 
correlation to this module, the authors focused on CRNDE 
(colorectal neoplasia differentially expressed), encoded 
by a gene located on chromosome 16 and expressing 
multiple splice variants [25, 26]. Initially identified as 
highly expressed in colorectal cancer [25], CRNDE is 
also upregulated in many other types of solid tumors and 
in leukemias and highly expressed in the early stages 
of human development (see [26] for a review). A recent 
study has shown that in tumoral cells CRNDE expression 
favors the metabolic switch to aerobic glycolysis [27], 
which is required during rapid cell proliferation. Based on 
these considerations, its expression principally in pre-B1, 
-B2, and CBs might be consistent with its function as 
a metabolic regulator. A further gene co-expression 
module identified by this study consisted of genes that are 
expressed mostly in CCs and CBs or absent/downregulated 
in the GC, including several lincRNAs genes. Among 
them, they called attention to RP11-132N15.3, a lincRNA 
primarily expressed in CBs and to some extent in CCs. 
RP11-132N15.3 gene is located approximately 240 kb 
upstream of BCL6 on chromosome 3. The transcriptional 
repressor BCL-6 is known to control a great number of 
target genes involved in multiple signaling pathways that 
modulate and promote the GC reaction [28]. Overall, these 
genes act together to increase the threshold of response to 
DNA damage, which enables genetic modifications of Ig 
genes, impairs premature activation of B-cells, and blocks 
their final differentiation to allow the production of high 
affinity antibodies. 
Among the few lncRNAs reported as differentially 
expressed during B-cell differentiation, we should mention 
the B-cell integration cluster (BIC), although a clear proof 
of BIC acting as a “long” RNA has not been found yet [29, 
30]. BIC consists of three exons spanning a 13 kb region 
at chromosome 21q21 and shows high expression level 
in antigen receptor stimulated B- and T-cells as well as in 
macrophages and dendritic cells upon Toll-like receptor 
stimulation. Since the processed products of this lncRNA, 
miR-155-5p and miR-155-3p, have a central role in several 
lnc-SENP5-4/
NCBP2 -AS2 MM 3q29 U Not described [111]
lnc-CPSF2-2 MM 14q32 U Not described [111]
lnc-LRRC47-1/
TP73-AS1 MM 1p36 U Not described [111]
lnc-ANGPTL1-3 MM 1q25 U Not described [111]
lnc-WHSC2-2 MM 4p16.3 U Not described [111]
Abbreviations: B-ALL, B acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; BL, Burkitt lymphoma; 
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM Multiple Myeloma.
a U = Uncharacterized; O = Oncogene; TS = Tumor Suppressor; OnP = Oncomir Progenitor
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biological processes, such as hematopoiesis, inflammation 
and immune responses [31], the studies related to BIC 
have been mainly focused on these miRNAs. Based on 
large-scale cloning studies [32], BIC has now been called 
MIR155 host gene or MIR155HG (http://www.genenames.
org/) whereas the BIC transcript is identified as pri-
miR-155. Notably, high expression levels of BIC and miR-
155 have been also found in many types of mature B-cell 
malignancies including diffuse large B-cell lymphoma 
(DLBCL) and chronic lymphocytic leukemia (CLL) [31]. 
LYMPHOMAGENESIS
B-cell malignancies are a heterogeneous group of 
neoplasms derived from mature or immature B-cells, and 
their phenotypic and biological characteristics largely 
mirror the normal development and maturation stages of 
B-cells. Similarly to most tumors, the coding genomes 
of malignant B-cells have numerous genetic aberration 
comprising deletions, amplifications and non-synonymous 
mutations. In addition, lymphomagenesis is characterized 
by the frequent occurrence of chromosomal translocations 
and aberrant somatic hypemutation, which are both 
related to the immunoglobulin remodeling mechanism 
including VDJ recombination, somatic hypermutation 
and class-switch recombination. Indeed, VDJ somatic 
recombination is carried out by two enzymes encoded 
by recombinase activating genes (RAG1 and RAG2) that 
break double stranded DNA, normally followed by the 
DNA repair process that resolves and fixes the breaks. 
However, such breaks can contribute to chromosomal 
translocation in lymphoma. In addition, the function of 
the physiological somatic hypermutation mechanism 
in malignant B-cell may be aberrantly extended to non-
immunoglobulin genes that are not targeted in healthy GC 
B-cells. In line with this, the genome of different subtypes 
of GC-derived lymphomas presents different recurrent 
primary chromosomal translocations and aberrant somatic 
hypermutations contributing to their pathogenesis [28] 
(Figure 2).
LNCRNAS IN B-CELL MALIGNANCIES
The raising importance of lncRNAs in all types 
of cancer, suggests that they might be protagonist in the 
pathogenesis of B-cell malignancies. Although thus far 
only few lncRNAs have been identified and extensively 
characterized, the list is expected to grow exponentially in 
the near future (Table 2 and Figure 2).
B-acute lymphoblastic leukemia (B-ALL)
B-acute lymphoblastic leukemia (B-ALL) is the 
most frequent infancy tumor and one of the main reasons 
of death associated with cancer in children and young 
adults. In B-ALL, mutations and translocations occurring 
in precursor B-cells result in dysregulated gene expression 
[33, 34]. To date, the comprehension of the molecular 
pathogenesis of B-ALL has greatly improved; however, 
the precise function of lncRNAs in the disease is still 
largely to be defined.
Fernando et al. [35] undertook a microarray study to 
define patterns of lncRNAs expression in three different 
subsets of B-ALL (t(12; 21), TEL-AML1; t(1;19) E2A-
PBX1; and t(4;11) MLL-AF4) finding that lncRNAs 
expression segregated with cytogenetic subtypes. Among 
the four most differentially regulated lncRNAs (BALR-
1, BALR-2, BALR-6, and LINC00958) high expression 
of BALR-2 (B-ALL associated long RNA-2), encoded 
by a locus on chromosome 7q21.2, correlated with a 
worse overall survival (OS) and a reduced response to 
prednisone treatment in a large cohort of B-ALL cases. 
Knockdown of BALR-2 resulted in growth inhibition 
and increased apoptosis of B-ALL cell lines both at 
baseline and after glucocorticoid treatment. On the 
contrary, constitutive expression of BALR-2 resulted in 
enhanced cell proliferation and resistance to prednisone 
administration. To note, gene expression analyses of 
cells with knockdown of BALR-2 revealed activation of 
several genes, such as FOS, JUN and BIM, involved in the 
glucocorticoid receptor signaling pathway in both human 
and murine B-ALL cell lines. These results suggest that 
BALR-2 may act in promoting B-ALL cells survival via 
inhibition of genes downstream of the glucocorticoid 
receptor. 
In another study [36], the same Authors focused 
on BALR-6 (B-ALL associated long RNA-6), expressed 
at the highest levels in MLL-translocated cases. [35]. 
The genomic location of BALR-6 in humans is at 
3p24.3. BALR-6 showed some similarities with BALR-2 
as silencing of BALR-6 in human B-ALL cell lines led 
to decreased cell proliferation and increased apoptosis, 
whereas overexpression of BALR-6 isoforms in both 
human and murine cell lines induced increased growth 
and a partial resistance to prednisolone treatment. 
Furthermore, BALR-6 overexpression in vivo in murine 
BM transplantation elicited a significant increase in 
hematopoietic progenitors, indicating that its deregulation 
may induce developmental alterations. Gene expression 
analyses of cells with knockdown of BALR-6 revealed 
enrichment for leukemia-associated genes and biological 
programs controlled by the transcription factor SP1. 
Luciferase reporter assays measuring the transcriptional 
activity of the promoter of two SP1 targets (CREB1 and 
p21) in HEK 293T cells demonstrated a great increase 
for both the promoter following SP1 and BALR-6 co-
overexpression. 
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Chronic lymphocytic leukemia (CLL)
CLL is the most frequent form of adult leukemia 
in Western countries [37, 38]. The characteristic mark of 
CLL is the clonal expansion of mature B-lymphocytes 
with a well-defined phenotype (CD19+, CD5+, CD23+, 
CD22 low, and low density of surface Igs), which can 
infiltrate multiple organs including lymph nodes, the 
BM, spleen, and liver. CLL has a highly heterogeneous 
clinical evolution, ranging from an indolent behavior in 
most patients not requiring treatment at diagnosis and 
possibly surviving for decades, to a rather rapid aggressive 
disease (nearly 30%) that requires treatment. These 
clinical differences have been associated with a number of 
biological markers, such as chromosomal aberrations (13q, 
11q and 17p deletions and trisomy 12), mutational status 
of the V region of the heavy-chain locus of the Ig genes 
(IGHV), TP53 disruptions, CD38 and ZAP-70 expression, 
largely investigated with prognostic purposes [39-41]. 
However, these parameters largely fail to elucidate the 
heterogeneity in the evolution of the patients. Sequencing 
of the full genome and exome has clarified the mutational 
scenery of CLL, even though the molecular mechanisms at 
the base of the origin and evolution of the disease remain 
largely unknown. 
Concerning lncRNAs with a potential pathogenetic 
role in CLL, great attention has been devoted to the deleted 
in leukemia 1 (DLEU1) and 2 (DLEU2) lncRNAs, which 
are located in the critical region at chromosome 13q14.3 
found to be deleted in more than 50% of CLL patients 
[42, 43]. DLEU2 hosts the miR-15a/16-1 cluster, known 
to have a central role in the pathogenesis of CLL, in part 
by increasing the expression of the oncogene BCL2 [44, 
45]. Mir-15a and mir-16-1 precursors are within intron 4 
of DLEU2, on the same chromosome strand. Mice deleted 
for the entire minimal deleted region within 13q14, 
comprising the Dleu2 lncRNA, were able to develop 
clonal B-cell proliferations recapitulating the spectrum of 
CLL in humans, showing a stronger aggressive phenotype 
than miR-15a/16-1-deleted mice [46]. A remarkable 
inhibitory effect of DLEU2 was observed on cellular 
growth and colony-forming ability of cancer cell lines 
in a miR-15a/16-1-dependent manner [47]. In addition, 
DLEU2 expression negatively regulated the Cyclin D1 and 
Cyclin E1 protein levels in a way reliant on the expression 
of miR-15a/16-1. Besides the deletion at 13q14.3, Garding 
et al. [48] suggested that the tumor suppressor activity 
at this region is multifactorial and probably involves 
further genetic elements than miR-15a/16-1, providing 
insights into the epigenetic regulation of all the genes in 
that region. In particular, the Authors found DLEU1 and 
the DLEU2/Alt1 isoform significantly and frequently 
demethylated in CLL. These two lncRNAs upregulation 
is connected with the in cis transcriptional downregulation 
of DLEU2 and miR-15a/16-1, and of a cluster of adjacent 
protein-coding tumor suppressor genes regulating NF-kB 
activity. Taken together, these findings have suggested 
that loss of DLEU2 might contribute to CLL through 
the absence or functional loss of miR15a/16-1, although 
additional roles, as described above [48], for DLEU2 in 
CLL pathogenesis might be postulated.
The participation of lncRNAs in the p53 pathway 
in CLL and lymphoma was firstly revealed by Blume 
et al. [49]. After triggering the p53-dependent DNA 
damage response or non-genotoxic activation of p53 
they identified two lncRNAs, nuclear enriched abundant 
transcript 1 (NEAT1) and lincRNA-p21, as p53 targets in 
primary CLL and in a series of Burkitt’s lymphoma cell 
lines. A strict p53 dependent regulation was proven for 
both the lncRNAs by deletion and knockdown of p53 in 
lymphoma cell lines and by showing p53 binding to the 
NEAT1 promoter. Furthermore, exposure of primary CLL 
cells to nutlin-3, a MDM2 inhibitor, induced both NEAT1 
and lincRNA-p21 transcription in a p53-dependent manner. 
LincRNA-p21 was primarily identified in the mouse, 
located on the chromosome 17, ∼15Kb upstream and on 
the opposite strand to the gene encoding the cell cycle 
regulator CDKN1A (also known as p21) [50]. Its human 
ortholog (also known as TP53COR1) maps to chromosome 
6p21.2, antisense and in close proximity of the CDKN1A 
gene [51]. LincRNA-p21 was demonstrated to repress gene 
transcription upon p53 activation in mouse [50] and to 
intervene in p53-dependent transcriptional suppression in 
human HeLa cells and mouse embryonic fibroblasts [51]. 
NEAT1, encoded on chromosome 11q13.1, is kept in the 
nucleus where it constitutes the core structural element 
of the paraspeckle sub-organelles, nuclear domains 
implicated in mRNA nuclear retention [52]. Notably, it 
has been shown that NEAT1 regulates the nuclear keeping 
of mRNAs encompassing inverted repeats (principally 
Alu sequences), that can shape double stranded RNA 
regions liable to adenosine-to-inosine editing, leading to 
translational repression [53]. These findings suggest that 
p53 activation may affect the expression of numerous 
genes at post-transcriptional level through NEAT1.
Recently, Sattari et al. [54] investigated the lncRNA 
myocardial infarction associated transcript (MIAT) in 
leukemia/lymphoma cell lines encompassing almost 
completely the hematopoietic cell lineages showing 
upregulation in lymphoid lineage with mature B-cell 
phenotype, including CLL and NHL. Furthermore, the 
analysis of MIAT expression level in primary CLL samples 
demonstrated higher incidence of MIAT upregulation 
in aggressive types of CLL defined by chromosome 
abnormalities (17p del > 11q23 del = Trisomy 12, 
compared to indolent form carrying 13q-deletion) and 
worst clinical outcome. MIAT was originally identified 
within a susceptible locus for myocardial infarction on 
chromosome 22q12.1 [55]. MIAT accumulates within the 
nucleus as RNA component of specific nuclear bodies 
where it may affect RNA splicing by binding to splicing 
factors and exert a regulatory effect on gene expression 
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[56]. The mouse homologue of MIAT, Gomafu, has been 
reported to bind to Oct4 gene, enhancing the expression 
of Oct4 transcription factor in embryonic stem cells. On 
the other hand, Oct4 binds to and positively regulates 
Gomafu transcription, thus constituting a regulatory 
feedback loop in the modulation of mouse embryonic stem 
cells pluripotency [57]. Similarly, MIAT was shown to 
constitute a regulatory loop with OCT4 in tumoral mature 
B-cell and both MIAT and OCT4 were demonstrated 
to be essential for cell survival [54]. Overall, these 
findings suggest an involvement of MIAT in supporting 
proliferation of the malignant mature B-cells.
A lncRNA gene, BM742401, whose lower 
expression in patients affected by gastric cancer was 
correlated with poor survival [58], was recently reported 
as frequently methylated in CLL [59]. More specifically, 
the promoter of BM742401 was unmethylated in normal 
CD19-sorted peripheral B-cells, but methylated in four 
out of five CLL cell lines and in about 50% of primary 
CLL samples at diagnosis. Methylation of BM742401 in 
CLL cell lines was inversely correlated with expression; 
treatment with a hypomethylating agent led to promoter 
demethylation and re-expression of BM742401 transcript. 
Interestingly, in CLL samples BM742401 methylation was 
significantly associated with higher lymphocyte counts 
and correlated with the advanced Rai stage (≥ stage 2), 
which represent poorer prognostic factors in CLL. 
Stable overexpression of BM742401 in a cell line with 
methylated BM742401, resulted in inhibition of cellular 
proliferation and enhanced apoptosis, suggesting a tumor 
suppressive role of BM742401 in CLL. However, the exact 
mechanism of tumor suppressive function of this lncRNA, 
localized to chromosome 18q11.2, is not fully understood 
and warrants further studies.
Besides investigations on selected candidates, only 
a few studies on global lncRNA expression have been 
performed in CLL. Ferreira et al. [60] performed deep 
RNA-sequencing in a cohort of 98 patients identifying 
1089 genes differentially expressed in normal (naïve 
and memory B-cells) and tumor samples. In addition 
to protein-coding genes, the differentially expressed 
transcriptional elements included 127 lncRNAs, of which 
47 were lincRNAs, and 61 pseudogenes [60]. More 
recently, Ronchetti et al. [61] looked for the lncRNA 
expression profiles in a wide prospective cohort of 217 
Binet A patients and various subtypes of healthy B-cells, 
derived from tonsils or peripheral blood lymphocytes. All 
samples were profiled on Affymetrix Gene 1.0 ST array. 
LncRNA expression was revealed applying a custom 
pipeline capable to re-annotate the probes comprised in 
array based on the LNCipedia-v3.1 database. This strategy 
enabled the investigation of the expression levels of 
nearly two thousand well-annotated and specific human 
lncRNAs. They recognized a signature composed of 24 
lncRNAs specifically dysregulated in CLL in respect to 
the healthy B-cell counterpart, such as naïve and memory 
B-cells. Furthermore, characteristic lncRNA signatures 
were identified in subgroups of patients prognostically 
stratified relying on cellular, molecular and cytogenetic 
markers, such as unmutated (UM) IGHV status, CD38 
expression, 11q and 17p deletions, and NOTCH1 
mutations. Among lncRNAs frequently associated 
with the presence of unfavorable prognostic markers, it 
deserves to be mentioned lnc-AC004696.1-1, also noted as 
ZNF667-AS1, which is localized at 19q13, antisense and 
head to head to ZNF667 gene. This lncRNA exhibited the 
highest expression in UM-CLLs, as previously shown by 
Ferreira et al. [60], and was negatively related to a short 
progression-free survival (PFS). The positive correlation of 
ZNF667-AS1 with its antisense overlapping gene ZNF667 
prompts a possible role in cis regulation. Interestingly, 
ZNF667 was demonstrated to be a transcriptional 
regulator of the antiapoptotic gene Bax in rat [62]. Finally, 
the study by Ronchetti et al. proposed an independent 
risk model, based on the expression of two lncRNAs, lnc-
IRF2-3 and lnc-KIAA1755-4, able to differentiate three 
prognostic groups in the set of early-stage CLL samples 
investigated. Specifically, the model identified a “high-
risk” group in which both lncRNAs were simultaneously 
expressed, whereas a “low-risk” group with the better PFS 
included the patients with a concomitant low expression 
of both lncRNAs. The divergent expression level of the 
two lncRNAs characterized the “intermediate-risk” group. 
To note, the model was shown to be independent from 
other known predictive factors in CLL and from a recently 
defined progression-risk score [63].
Mantle cell lymphoma (MCL)
Mantle cell lymphoma (MCL) is a relatively 
uncommon, B-cell NHL predominantly affecting men 
older than 60 years. Although an aggressive disorder, 
it can have a more indolent course in some patients. 
These lymphomas are most likely to arise from early 
B-cells in the outer edge (mantle zone) of the lymph 
node follicle and most harbor the t(11;14)(q13;q32) 
translocation leading to the overexpression of Cyclin D1 
[64]. MCL cells are typically CD5+ and CD23-, with 
high density of surface IgM/D. To date, one of the few 
noteworthy studies investigating the role of lncRNAs in 
MCL has based its assumptions on the observation that 
inhibition of the mammalian target of rapamycin (mTOR) 
is a strategic and hopeful way to treat MCL, which 
frequently shows activation of and dependence on the 
mTOR pathway for cell proliferation and survival [65]. 
Specifically, Mourtada-Maarabouni and Williams [66] 
used RNA interference in MCL cell lines to downregulate 
the lncRNA Growth Arrest Specific (GAS5), a cell-
cycle arrest and apoptosis-related lncRNA with tumor 
suppressor activity [67-71], based on the fact that it is 
a known effector of the mTOR pathway in normal and 
transformed T lymphocytes [72, 73]. In line with this, also 
in MCL cells GAS5 downregulation markedly diminished 
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the effects of each mTOR antagonists on cell viability, 
DNA synthesis, and colony-forming power. These findings 
indicate that regulating GAS5 may provide a new target for 
improvements in chemotherapy exploiting the dependence 
of MCL cells on the mTOR pathway.
Recently, Wang et al. [74] investigated the role 
in MCL of metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1), a putative oncogenic lncRNA of 
more than 8000 nucleotides transcribed from chromosome 
11q13 and overexpressed in several solid tumors [75, 76]. 
They detected MALAT1 overexpression in human MCL 
tissues and cell lines in confront with normal B-cells, 
showing a correlation with high International Prognostic 
Index (IPI) and lower OS of MCL patients. Knockdown 
of MALAT1 hampered cell proliferation and enhanced 
apoptosis rates of MCL cell lines. Furthermore, Wang 
et al. demonstrated a raised expression of CDKN1A/p21 
and CDKN1B/p27 after MALAT1 silencing, whereas the 
levels of EZH2 and H3K27me3 protein expression were 
both reduced. The Authors suggested a MALAT1 signaling 
in MCL in which MALAT1 recruits the PRC2 complex 
by binding to EZH2 finally targeting CDKN1A/p21 and 
CDKN1B/p27 genes. p21 and p27 expression is then 
epigenetically repressed by H3K27me3. The consequent 
activation of cyclin-dependent kinase 1 and 2, due to p21 
and p27 downregulation, promotes the phosphorylation of 
EZH2 further increasing its binding to MALAT1, which 
in turn enhances EZH2-mediated H3K27me3, and p21 
and p27 genes repression. The result is an uncontrolled 
cell proliferation, providing MALAT1 of some oncogenic 
properties.
Follicular lymphoma (FL)
Follicular lymphoma (FL) is the second kind 
of NHL by frequency, generally characterized by a 
heterogeneous clinical course. From a biological point of 
view, FL cells are malignant counterparts of normal GC 
B-cells. Based on the relative ratio of CCs and CBs, FL 
grades 1 to 3 are recognized with a further distinction of 
grade 3A and 3B [77]. FL grades 1 to 3A have common 
histologic and molecular characteristics and an indolent 
clinical course, whilst FL grade 3B histologically looks 
like DLBCL, shows different molecular features and 
is clinically more aggressive. The genetic trait of FL is 
the translocation t(14;18)(q32;q21), resulting in the 
constitutive overexpression of the antiapoptotic BCL2 
protein, which confers a survival advantage to FL cells. 
Although dysregulated BCL-2 expression appears to 
be fundamental in the pathogenesis of FL, it does not 
explain the entire pathogenesis of the disease. Even other 
chromosomal aberrations or gene mutations found in FLs, 
such as the translocations involving the BCL6 gene locus 
[78] or the EZH2 mutations [79], are not sufficient for 
explaining the mechanisms involved in lymphomagenesis.
In a recent study of lncRNA expression profiling 
by microarray, Pan et al. compared three FL3A with 
three reactive lymphatic nodes (RLN) [80]. They found 
statistically significant the upregulation of 152 lncRNAs 
and the downregulation of 37 lncRNAs comparing the 
FL3A and RLN groups. Four of the dysregulated lncRNAs 
were then validated by qRT-PCR in an independent group 
of 5 FL3A patients and 5 RLN. The most interesting 
finding was that RP11-625 L16.3 (an antisense lncRNA 
located on chromosome 12) was significantly upregulated 
in FL3A patients, even if its biological functions are not 
clear yet.
Diffuse large B-cell lymphoma (DLBCL)
DLBCL is the most frequent form of NHL in 
adults and represents a biologically heterogeneous and 
clinically aggressive group of disease entities classified 
based on morphology, immunophenotype, genetic 
aberrations, and clinical ongoing [77]. The majority of 
DLBCLs arises from antigen-exposed B-cells during 
the GC reaction, a process that optimizes the affinity of 
antibodies for antigens [81]. According to the cell of origin 
transcriptional classification, which relates subsets of 
DLBCL to specific stages of normal B-cell development, 
this type of lymphoma can be assigned to either a germinal 
center-B (GCB) or activated-B-cell (ABC) subtype [82]. 
The GCB subtype is preferentially diagnosed in young 
patients with a clinical outcome more favorable than the 
ABC subtype. Despite significant progress in diagnosis 
and treatment, a wide number of DLBCL patients still 
experiences a poor prognosis outcome. Thus, searching 
for novel molecular biomarkers associated with DLBCL 
pathogenesis, including lncRNAs, has been the aim of 
an increasing number of studies in recent years. As a 
result, a crucial involvement in the molecular etiology of 
DLBCL, as well as a potential relevance as markers of 
poor prognosis and therapeutic targets of the disease, have 
been suggested for different lncRNAs
Chromosome 1q25.1 has been associated with 
DLBCL because of recurrent breakpoints or duplication 
events [69, 83]. Notably, encoded at 1q25.1 locus is 
GAS5 (see above), which was identified as a new non-Ig 
partner gene deregulating BCL6 expression in a DLBCL 
case presenting the t(1;3)(q25;q27) [69]. In this patient, 
the GAS5-BCL6 fusion transcripts were expressed in a 
preferential manner from the derivative chromosome 3, 
instead of BCL6 from the normal allele.
Lu et al. [84] found that lnc-RP11-211G3.3.1-1 
gene in LNCipedia lncRNA database [1] is located in a 
region where the majority of the BCL6 gene translocations 
breakpoints occurs. This lncRNA is transcribed antisense 
to BCL-6 locus and, remarkably, its boundaries match 
those of the BCL6 translocation zone quite precisely. 
Moreover, this lncRNA is a natural transcript in human 
DLBCL: expression of lnc-RP11-211G3.3.1-1 was 
detected in the GBC subtype of DLBCL and at a lower 
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level in the ABC subtype (Griffith M, Marra MA. http://
www.alexaplatform.org/alexa_seq/DLBCL_ABC_GCB/
genes/chr3_6/ENSG00000223401.htm. Accessed August 
24, 2015).
Conde et al. [85] carried out a copy number 
variation analysis of 681 NHL patients and 749 controls, 
to correlate frequent structural alterations and lymphoma 
susceptibility. The Authors reported that the partial 
duplication of the 3’-region of the LOC283177 lncRNA 
located at 11q25 could be associated with DLBCL risk. 
While the biological significance of LOC283177 in 
DLBCL remains to be investigated, they suggested that 
it could be a possible susceptibility locus for the disease. 
Remarkably, in the younger DLBCL group LOC283177 
was associated with risk at a slightly higher degree than 
when considering the entire set of DLBCL patients. The 
duplication seems then to be more distinctive of the GCB 
than of the ABC DLBCL subtype; however, these findings 
need to be validated independently.
Peng et al. [86] investigated the role of lncRNA 
LUNAR1 (LeUkemia-induced Non-coding Activator 
RNA-1) in DLBCL. This lncRNA is located at 15q26.3 
and was firstly identified in human primary T-cell acute 
lymphoblastic leukemia (T-ALL) where it is upregulated 
in NOTCH1 mutated cases. Furthermore, it is essential 
for efficient T-ALL growth in vitro and in vivo due to 
its ability to enhance the expression of its neighboring 
coding gene, IGF1R, thus sustaining the IGF1 signaling 
[87]. The levels of LUNAR1 expression in DLBCL patient 
tissues and in six DLBCL cell lines were higher than in 
normal specimens. A significant correlation of the greater 
expression of LUNAR1 with stage, rituximab treatment, 
and IPI was observed. Furthermore, LUNAR1 expression 
functioned as an independent predictor for OS and PFS. 
LUNAR1 silencing significantly inhibited cell proliferation 
of OCI-LY-7 DLBCL cell line, arresting the cells at 
the G0-G1 phase, and E2F1, Cyclin D1 and p21 were 
identified as functional targets of LUNAR1 in DLBCL. 
The same group [88] identified lincRNA-p21 (see 
above) as a possible new prognostic biomarker/ indicator 
of poor prognosis in DLBCL. LincRNA-p21 expression 
evaluated by PCR in pathological tissues and cell lines 
was markedly lower than in healthy specimens, and the 
level of expression was significantly linked to staging, B 
symptoms, performance status, IPI score and serum LDH. 
Cases with low lincRNA-p21 expression showed poorer 
OS and PFS rates. When ectopically expressed in OCI-
LY7 cell line, lincRNA-p21 repressed cellular growth 
and blocked cell cycle progression at the G0-G1 phase. 
Furthermore, high level of lincRNA-p21 downregulated 
Cyclin D1 and CDK4 expression and upregulated p21, as 
assessed by Western blot analysis in agreement with the 
evidence in human DLBCL tissues. Overall, these findings 
indicate that lincRNAp21 may act as a tumor suppressor 
possibly contributing to DLBCL development in case of 
lacking/reduced expression. 
Peng et al. [89] investigated also the expression 
levels of lncRNA PEG10 (paternally expressed 10), 
encoded from an imprinted gene located on chromosome 
7q21 [90], in a series of DLBCL patients and cell 
lines. PEG10 was found upregulated in DLBCL tumor 
tissues and cell lines matched with normal tissues and 
significantly correlated with B symptoms, IPI score, 
CHOP-like treatment and rituximab. The Authors 
proved that PEG10 was an important predictive factor 
for diagnosis and prognosis of the disease on the base 
of the follow-up of a large group of patients. PEG10 
knockdown in RCK-8 cell line inhibited cell proliferation 
and promoted apoptosis. To note, PEG10 was described 
as a direct transcriptional target of c-MYC in pancreatic 
and hepatocellular carcinoma cells [91]. Finally, Peng et 
al. [92] analyzed the expression levels of lncRNA HULC 
(highly up-regulated in liver cancer) in a cohort of DLBCL 
patients and cell lines and in 60 controls with reactive 
lymph nodes. This lncRNA, located at 6p24.3 has been 
found strongly overexpressed in human hepatocellular 
carcinoma [93, 94] and pancreatic cancer [95]. The 
expression levels of HULC in DLBCL patient tissues and 
in six DLBCL cell lines were significantly higher than in 
control specimens. Moreover, the greater expression of 
HULC was correlated with clinical stages, B symptoms, 
CHOP-like treatment, rituximab and IPI. To note, Peng 
et al. verified the importance of HULC as predictive 
factor for DLBCL diagnosis and prognosis in a sizable 
set of patients. HULC knockdown in SU-DHL-4 cell line 
significantly inhibited cell growth and promoted apoptosis 
by repressing Cyclin D1 and BCL2 proteins expression 
implicating a potential role for HULC as a therapeutic 
target in DLBCL.
The lincRNA HOTAIR (Hox transcript antisense 
intergenic RNA), encoded on chromosome 12q13.13, was 
found upregulated in DLBCL tumor samples, compared 
with normal tissues [96]. The upregulation of HOTAIR 
correlated with certain critical clinico-pathological 
characteristics, including clinical stage, B symptoms, IPI 
scores and tumor mass and predicted a poor prognosis 
in these patients. HOTAIR knockdown in RCK-8 cell 
line expressing high levels of this lncRNA, significantly 
reduced cell proliferation, arrested the cell cycle in the 
G2/M phase and stimulated cell apoptosis, probably 
through the PI3K/AKT/NF-kB pathway. 
To date only a few studies concerning global 
lncRNA expression have been reported in DLBCL. Sun 
et al. analyzed lncRNAs expression profiles and clinical 
characteristics in a large cohort of 1043 DLBCL patients 
identifying prognostic lncRNAs that were significantly 
associated with OS [97]. Based on microarray expression 
data, they constructed a six-lncRNA signature able 
to classify DLBCL patients into high- and low-risk 
subgroups with significantly diverse survival outcome, 
independently of all other clinical factors conventionally 
considered for survival prediction of patients. 
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Furthermore, the six-lncRNA signature was capable 
to predict effectively the survival outcome of DLBCL 
patients with similar IPI variables. Specifically, patients 
with low lncRNA expression-based risk score tended to 
express five lncRNAs (MME-AS1, CSMD2-AS1, RP11-
360F5.1, RP11-25K19.1 and CTC-467M3.1), whereas 
SACS-AS1 was upregulated in patients with high risk 
score. Functional enrichment analysis of protein-coding 
genes co-expressed with prognostic lncRNAs suggested 
that the six-lncRNA signature might be implicated in 
regulatory functions of known cancer-related pathways 
and immune system-related biological processes closely 
linked with the mechanisms of lymphomagenesis and 
progression of DLBCL.
A transcript discovery strategy set up on RNA-
sequencing of 116 primary tumors and normal B-cell 
specimens was used by Verma et al. to identify and 
characterize novel lncRNAs in DLBCL [98]. They 
recognized 2,632 new lncRNAs expressed in more than 
one patient, two-thirds of which were absent in normal 
B-cells. Many lncRNAs had more than one isoform, 
and more than one-third were differentially expressed in 
the ABC and GCB DLBCL subtypes. Correlations with 
protein-coding genes showed that > 80 % of lncRNAs 
were significantly co-expressed with at least one gene, 
suggesting possible co-regulatory mechanisms. Pathway 
analysis on the array of co-expressed coding genes for 
each lncRNA revealed that 43% of the lncRNAs showed 
enrichment for significant DLBCL-related functional 
pathways, such as CD40 pathways.
Burkitt lymphoma (BL)
Burkitt lymphoma (BL) is an aggressive GC 
B-cell-derived NHL that affects mostly children and 
young adults, particularly males [99]. BL is subdivided 
into three different categories based on epidemiological 
observations: endemic (rare outside Africa), sporadic 
(occurring throughout the world), and immunodeficiency-
associated [77]. Endemic BL is frequently associated 
with the Epstein-Barr virus (EBV) infection. 
Immunodeficiency-related BL is diagnosed predominantly 
in patients infected with HIV/AIDS, but can also occur 
in people who have inherited immune deficiencies or 
those who underwent organ transplant. The molecular 
hallmark of BL is translocation of the MYC oncogene, 
juxtaposing the MYC locus at 8q24 and one of three 
immunoglobulin loci. Eighty percent of BL patients have 
t(8;14) that juxtaposes the MYC gene with IGH enhancer 
elements on chromosome 14, resulting in the MYC 
constitutive transcriptional deregulation. In the remaining 
20% of BL tumors, translocations t(2;8) or t(8;22) 
place the MYC gene adjacent to either kappa or lambda 
light chain loci and enhancer elements, respectively. 
Even though the constitutive expression of MYC is 
considered the chief responsible for BL development, 
deregulation of this transcription factor by juxtaposition 
with the immunoglobulin loci seems not to be sufficient 
to drive lymphomagenesis. Indeed, further genetic lesions 
cooperate with MYC to generate the disease, as revealed 
by high-throughput sequencing approaches [100-102]. 
Furthermore, since MYC protein is central in many 
tumors by regulating the expression of thousands of target 
genes, it could also modify the expression of lncRNAs 
participating in oncogenic transformation. 
In order to identify MYC-regulated lncRNAs 
possibly involved in lymphomagenesis, Doose and 
colleagues examined RNA-sequencing data of patients 
from the major subtypes of mature B-cell lymphomas, 
namely BL, DLBCL, and FL, compared with data from 
healthy GC B-cells. The results were then crossed with 
those deriving from cell lines expressing inducible 
MYC to identify MYC-regulated lncRNAs [103]. They 
identified 13 lncRNAs differentially expressed in IG-
MYC-positive BL relative to normal GC B-cells and 
concordantly regulated by MYC in the model cell lines. 
In particular, they focused on the lncRNA that had the 
highest positive correlation with MYC expression in 
MYC-positive lymphomas, which they titled MYC-
induced long noncoding RNA (MINCR). The MINCR 
gene is intergenic to the GLI4 and ZNF696 coding genes at 
chromosome 8q24.3. MINCR knockdown was associated 
with reduced cellular proliferation in three different cell 
types. The investigation of gene expression changes 
induced by MINCR knockdown in the cell line where the 
effect was most pronounced (hT-RPE-MycER), showed 
a significant enrichment of genes involved in cell cycle 
initiation and progression among those downregulated. 
These genes showed a significant enrichment of MYC-
binding sites in their promoters, suggesting that MINCR 
may act as a modulator of the MYC transcriptional 
program. This model was supported by the observation 
that the promoters of selected cell cycle genes decreased 
MYC binding following MINCR knockdown.
Another study investigating the P493-6 B-cell line 
carrying an inducible MYC allele and primary MYC-
associated B-cell lymphoma samples, showed that 
lncRNAs are the principal element of the MYC-regulated 
transcriptional program [104]. In total, more than one 
thousand lncRNA loci were identified as regulated by 
MYC in the P493-6 model. Both MYC-induced mRNAs 
and lncRNAs but only MYC-repressed lncRNAs were 
significantly enriched for MYC binding sites. In addition, 
the Authors analyzed lncRNA differentially expressed in 
B-cell lymphoma with high and low MYC levels. Among 
them, a rate greater than 50% was even identified as 
MYC-regulated in P493-6 cells and was responsive to 
MYC knockdown in BL cell lines. All these data sustain 
the potential pathogenetic relevance of these lncRNAs.
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Multiple myeloma (MM)
Multiple myeloma (MM) is a fatal malignant 
proliferation of antibody-secreting BM PCs that accounts 
for 10% of all hematological malignancies. MM is 
characterized by a wide clinical spectrum ranging from a 
pre-malignant condition called monoclonal gammopathy 
of undetermined significance (MGUS), to extra-medullary 
myeloma/plasma cell leukemia (PCL) [105-107]. MM 
shows a severe genomic instability leading to both aberrant 
ploidy and structural rearrangements [105, 108]. Virtually 
half of MM tumors are hyperdiploid, the remaining ones 
are frequently associated with the constitutive activation 
of CCND1 (11q13), CCND3 (6p21), MAF (16q23), 
MAFB (20q11), or FGFR3/MMSET (4p16.3) genes, as a 
result of chromosomal translocations involving the IGH 
locus on chromosome 14q32. Despite the remarkable 
improvements in treatment and patient care [109], MM 
remains an incurable disease.
Data concerning lncRNAs involvement in MM are 
expanding. The first lncRNA found to be overexpressed 
in BM mononuclear cells of MM patients was MALAT1. 
Specifically, Cho et al. [110] found MALAT1 expression 
significantly higher in MM patients at diagnosis 
compared to treated patients or healthy individuals. In 
addition, patients who experienced disease progression 
or relapse showed a significant increased expression 
of MALAT1. A recent study by Ronchetti et al. [111], 
investigating lncRNA expression profiles in a large cohort 
of patients representing all the major different forms of 
PC dyscrasias, confirmed and extended these finding. 
Interestingly, MALAT1 upregulation was associated with 
molecular pathways related to cell cycle regulation, p53-
mediated DNA damage response, and mRNA maturation 
processes. Differently from the evidence of MALAT1 
overexpression in MM cells [110, 111], Isin et al. reported 
that circulating levels of MALAT1 transcripts were 
significantly lower in MM patients compared to healthy 
subjects [112]. Finally, it has been recently demonstrated 
that MALAT1 is overexpressed in mesenchymal stem cells 
(MSCs) from MM patients and regulates the transcription 
of the nearby antisense protein-coding gene LTBP3 
(latent TGF-β-binding protein) [113], known to positively 
regulate the activity of TGF-β, which may contribute 
to the inhibition of terminal osteoblastogenesis in MM 
[114]. More specifically, MALAT1 was shown to recruit 
the transcription factor SP1 on the LTBP3 promoter 
contributing to the increase of LTBP3 expression. Notably, 
knockdown of MALAT1 significantly decreased LTBP3 
transcription [113].
Maternally expressed gene 3 (MEG3), encoded at 
14q32.2, is a lncRNA with a tumor suppression function 
mediated by both p53-dependent and p53-independent 
mechanisms [115], whose expression is epigenetically 
regulated. Benetatos et al. [116] studied the expression of 
MEG3 in the context of MM and found that about 60% of 
patients presented hypermethylation of the differentially 
methylated region (DMR) of the MEG3 promoter. 
A correlation with the disease stage was observed as 
well as with the disease subtype; notably, 67.7% of the 
patients with IgG MM and 100% of the IgM MM had 
hypermethylated DMR, whereas none of the patients with 
IgA MM presented the specific epigenetic change. It was 
therefore suggested that promoter hypermethylation of the 
MEG lincRNA and the consequent decreased expression 
might be involved in MM tumorigenesis. Interestingly, 
MSCs from MM patients (MM-MSCs) showed MEG3 
expression levels lower than those from normal donors 
(ND-MSCs) during osteogenic differentiation [117]. 
Furthermore MEG3 overexpression in MM-MSCs 
could promote their osteogenic differentiation, whereas 
MEG3 knockdown compromised osteogenesis of ND-
MSCs. Experimental data suggested that MEG3 favors 
osteogenesis by targeting the transcription of BMP4 (Bone 
morphogenetic protein 4) gene. MEG3 and BMP4 both 
map on chromosome 14q but in opposite transcriptional 
orientation. In the proposed model, MEG3 may directly 
interact with the transcription factor SOX2 causing 
its detachment from the BMP4 promoter and finally 
increasing the expression of BMP4 [117]. 
Preliminary evidence has also suggested deregulated 
circulating levels of a few selected lncRNAs in MM 
patients compared to healthy donors (HD) [112]. A study 
by Isin et al. investigating the circulating levels of selected 
lncRNAs in plasma of patients with B-cell malignancies 
found that expression of the lncRNA taurine upregulated 
gene 1 (TUG1), transcribed from chromosome 22q12.2, 
was significantly different in plasma of patients with MM 
compared to healthy subjects [112]. Furthermore, higher 
levels of TUG1 correlated with disease state in both MM 
and CLL. TUG1 has been shown to be transcriptionally 
regulated by p53 in response to DNA damage and to be 
involved in repressing important cell cycle related genes 
by recruiting the Polycomb Repressive Complex 2 (PRC2) 
at chromatin level [118].
Besides studies on selected candidates, only 
few studies on lncRNA expression at genome-wide 
transcriptome level have been performed in MM. In 
particular, Zhou et al. [119] investigated a repertoire of 
2330 lncRNA from a large cohort of 559 MM patients 
by re-annotating different publicly available microarray 
datasets and developed a four-lncRNA prognostic 
signature predicting survival in MM patients. Notably, 
two of these lncRNAs were located respectively to 
chromosome 1p (RP1-43E13.2) and 1q (RP4-803J11.2) 
which are found to be lost or gained in a significant 
fraction of MM and associated with an adverse prognosis. 
More recently, Ronchetti et al. [111], investigated 
global lncRNA expression profiles by new generation 
microarrays in a large cohort of 259 patients, representing 
all the major different entities of PC dyscrasias, including 
MGUS, asymptomatic smoldering MM (SMM), truly 
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overt and symptomatic MM, and extra-medullary MM/
PCL patients, in addition to nine HD. The Authors 
analyzed the expression of 1852 lncRNAs specified 
by unique probes on the array and found that 230 
lncRNAs were able to well distinguish normal versus 
pathological samples as well as the different forms of 
PC dyscrasias. Furthermore, 31 lncRNAs, including 
MALAT1 (see above), were found specifically deregulated 
in pathological samples compared to normal BM PCs. In 
addition, 21 lncRNAs displayed progressively deregulated 
expression in association with more aggressive form of 
the disease. Among these, lnc-SENP5-4, lnc-CPSF2-2, 
and lnc-LRRC47-1 were found significantly differently 
expressed in a panel of 19 MMs at diagnosis compared 
to the corresponding relapse/PCL phases. Notably, 
a recent study investigating lnc-LRRC47-1 in MM, 
confirmed its progressive downregulation from normal 
PCs to MGUS and symptomatic disease, which appeared 
independent from the methylation status of its promoter 
[120]. Furthermore, the 21 lncRNA list included GAS5 
and lnc-ANGPTL1-3, both located at 1q25, a finding 
in agreement with the GEP-model for high-risk MM 
characterized by the expression of many genes mapping 
to chromosome 1q [121]. Interestingly, GAS5 was 
found significantly upregulated in MMs with 1q gain. 
Concerning other main genomic alterations in MM, 
Ronchetti et al. found a significant downregulation of 
DLEU2 in patients carrying del13; in addition, DLEU2 
expression significantly correlated with that of miR-15a 
and miR-16-1. Considering MM patients carrying t(4;14), 
it is of relevance the upregulation of lnc-WHSC2-2 that 
maps intronic and antisense to the translocation target 
gene MMSET. Notably, the consistent deregulation of 
lnc-WHSC2-2 in translocated MM resembles that of 
snoRNA ACA11 that maps in the adjacent 3’ intron of 
MMSET on the sense strand [122, 123]. It is conceivable 
that, as reported for ACA11 [123], lnc-WHSC2-2 may be 
a critical target of the t(4;14) translocation in MM with 
a potential oncogenic role. Finally, the 1q-gain MM 
group showed significantly upregulated seven lncRNAs 
all located at 1q region, suggesting that gene dose effect 
may also be a mechanism behind lncRNAs deregulation. 
Notably, Ronchetti et al. extended the study on the role 
of lncRNA deregulation in MM, based on the emerging 
evidences of the cross-regulation between lncRNAs and 
miRNAs. In particular, they investigated in silico the 
miRNA/lncRNA relationship in MM and PCL tumors 
and in normal PC samples, by integrating expression data 
with target predictions. They identified lncRNA-miRNA 
pairs (lnc-MCL1-2 and mir-17 gene family; lnc-AGBL1-4 
and mir-185-5p; lnc-DLEU2 and miR-3175; LINC00173 
and miR-221) with potentially relevant interactions for 
MM biology, providing an interesting suggestion of the 
pathological impact of miRNA/lncRNA cross-talk in MM 
[124].
LNCRNA-BASED THERAPEUTIC STRATEGIES
As discussed above several studies have 
revealed a high number of deregulated lncRNAs in 
B-cell malignancies, but only a few have been deeply 
characterized so far. Based on their correlation with 
prognosis, OS or drug-response, some lncRNAs prompt 
further investigation to be introduced in pre-clinical and 
clinical practice. Nowadays, lncRNA-based therapeutic 
approaches represent a challenging avenue of research 
largely heartened by the encouraging results obtained 
with miRNAs-based strategies. Indeed, miR-29b [125] 
mimics as well as miR-221/222 inhibitors are promising 
anti-MM therapeutic agents when administered in vitro 
and in vivo in human myeloma cell lines or in human 
MM xenografts mice [126, 127]. In line with this, the loss 
of function of distinct lncRNAs could be overcome by a 
replacement therapy that reintroduces such lncRNAs into 
cells as drugs, whereas when lncRNAs are upregulated in 
cancer, three main tools could be exploited to affect their 
expression: the use of short interfering RNAs (siRNAs), 
Antisense Oligonucleotides (ASOs), or locked nucleic 
acid (LNA) nucleosides. SiRNAs are double stranded 
DNA molecules that exactly bind a stretch of nucleotides, 
resulting in RNA target degradation. ASOs are single 
stranded molecules smaller than siRNAs and, therefore, 
able to enter more easily into the nucleus, where lncRNAs 
are often localized. ASO molecules were used in vivo and 
in vitro against MALAT1 resulting in a reduction of lung 
cancer metastasis formation [128]. LNA nucleosides are 
nucleic acid analogues with the ribose ring “locked” by 
a methylene bridge. Thanks to this modification, LNA 
oligonucleotides demonstrate extraordinary hybridization 
affinity toward both RNA and DNA, with excellent 
mismatch discrimination. Finally, the genetic editing 
offers a valid alternative to lncRNAs knockout mediated 
by siRNA or ASO, by targeting the genomic DNA straight. 
The most recent genetic tool available for this purpose 
is the clustered regularly interspaced short palindromic 
repeats (CRISPR)/CRISPR-associated (Cas) system [129]. 
Notably, the CRISPR/Cas9 system and paired single 
guide RNAs (sgRNAs) is able to produce large fragment 
deletions.
In the next future, these approaches will be 
fundamental to discover the biological function of 
lncRNAs in cells. Data from these studies are arousing 
great interest among the scientific community and will 
be central for the future growth of this novel class of 
therapeutic agents [130, 131]. However, therapeutic 
applications of lncRNAs, as for RNA in general, must deal 
with considerable obstacles, including improvement of 
reliable delivery systems, dosage regimes and techniques 
to reduce off-target effects. Moreover, we should not 
overlook the problems related to targeting transcripts the 
size of lncRNAs due also to their extensive secondary 
structures. Finally, it is essential to develop more genetic 
Oncotarget14www.impactjournals.com/oncotarget
model systems aimed at understanding the function of 
lncRNAs in vivo. Notwithstanding all these limits to be 
overcome, lncRNAs seem to be promising therapeutic 
targets.
CONCLUSIONS
LncRNAs represent a very large and complex family 
of protein-non coding transcripts with an emerging pivotal 
role in many molecular and physiological processes 
associated with the biology of normal and cancer cells. 
As for miRNAs, also lncRNAs may have strong potential 
as novel diagnostic and prognostic biomarkers in cancer, 
mainly due to the evidence of their tissue-specific 
expression and their easy detection in body fluids, and may 
represent novel therapeutic agents or targets. However, the 
genomic annotation of lncRNAs is currently limited.
In this review, we summarized and discussed 
the current knowledge about normally expressed and 
dysregulated lncRNAs during B-cell differentiation and 
in B-cell malignancies that in many instances represent 
cells blocked at different stages of maturation. As it is the 
case of other types of cancer, the investigation of lncRNAs 
in B-cell malignancies is still in its infancy. Several 
studies have revealed a high number of lncRNAs that are 
deregulated in B-cell malignancies, but only a few have 
been extensively characterized, prompting the need for 
further investigations. Furthermore, the global expression 
profiling of lncRNAs in these malignancies is still limited; 
most of the available data have been generated by PCR 
or microarray based-studies and need to be validated in 
large series of patients and with more extensive use of 
innovative technical approaches such as RNA-sequencing. 
Based on these considerations, we believe that exploring 
the landscape and functions of lncRNAs in normal B-cells 
and in their malignant counterparts will represent a 
compelling and challenging task in the next future with an 
important biological and clinical impact in the field.
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